lysosom
membranebound
organel
role
process
involv
degrad
recycl
cellular
wast
cellular
signal
energi
metabol
defect
gene
encod
lysosom
protein
caus
lysosom
storag
disord
enzym
replac
therapi
prove
success
grow
evid
also
implic
role
lysosom
dysfunct
common
diseas
includ
inflammatori
autoimmun
disord
neurodegen
diseas
cancer
metabol
disord
focu
lysosom
dysfunct
autoimmun
disord
neurodegen
diseas
includ
lupu
rheumatoid
arthriti
multipl
sclerosi
alzheim
diseas
parkinson
diseas
review
critic
analys
progress
opportun
therapeut
target
lysosom
protein
process
particularli
small
molecul
peptid
drug
discov
christian
de
duve
lyso
some
membran
bound
vesicl
contain
numer
hydrolyt
enzym
break
biolog
polym
protein
lipid
nucleic
acid
polysaccharid
lysosom
long
known
key
role
degrad
recycl
extracellular
materi
via
endocytosi
phagocytosi
intracellular
materi
via
autophagi
review
elsewher
fig
product
lyso
somal
degrad
process
traffick
golgi
apparatu
reus
releas
cell
lysosom
exocytosi
import
immun
system
process
addit
becom
clear
recent
lysosom
import
role
cellular
process
includ
nutrient
sens
control
energi
metabol
fig
alter
lysosom
function
either
fusion
process
involv
gener
pathway
mention
relat
function
lyso
somal
enzym
non
enzymat
protein
result
broad
detriment
effect
includ
failur
clear
potenti
toxic
cellular
wast
inflamm
apopto
si
dysregul
cellular
signal
defect
implic
mani
diseas
rang
rare
lysosom
storag
disord
lsd
caus
dysfunct
particular
lysosom
protein
common
autoimmun
neurodegen
di
order
despit
limit
impress
result
achiev
treat
sever
lsd
enzym
replac
therapi
ert
addit
sub
stantial
effort
focus
therapeut
target
autophagi
process
upstream
lyso
some
howev
far
less
attent
investig
potenti
directli
target
lysosom
small
molecul
peptid
drug
nevertheless
recent
advanc
understand
ing
lysosom
function
dysfunct
di
eas
promis
novel
opportun
therapeut
intervent
target
lysosom
specif
begin
emerg
review
provid
brief
overview
lysosom
biogenesi
structur
function
describ
role
lysosom
dysfunc
tion
lsd
well
common
diseas
specif
articl
focu
organ
specif
non
organspecif
autoimmun
diseas
includ
lupu
rheumatoid
arthriti
ra
multipl
sclerosi
ms
extens
review
elsewher
also
briefli
highlight
neurodegen
er
disord
alzheim
diseas
ad
parkinson
diseas
pd
illustr
breadth
natur
emerg
therapeut
opportun
current
toolbox
pharmacolog
agent
modul
lysosom
function
emerg
novel
tar
get
strategi
set
indic
high
light
note
therapeut
approach
treat
inflammatori
autoimmun
diseas
aim
inhibit
deleteri
excess
lysosom
activ
wherea
lysosom
activ
would
goal
treatment
neurodegen
diseas
although
beyond
scope
review
approach
may
applic
diseas
lysosom
may
play
role
includ
cancer
metabol
diseas
age
review
elsewher
format
matur
lysosom
complex
process
involv
fusion
late
endosom
contain
materi
taken
cell
surfac
transport
ve
icl
bud
tran
golgi
network
vesicl
contain
nearli
differ
hydrolyt
enzym
group
nucleas
proteas
phosphatas
lipas
endocytosi
vesiclemedi
process
cell
engulf
membran
extracellular
materi
sever
endocyt
pathwaysphagocytosi
pinocytosi
receptormedi
endocytosi
util
differ
mechan
intern
materi
clathrinmedi
endocytosi
major
endocyt
pathway
mammalian
cell
fig
central
posit
lysosom
crossroad
major
autophag
pathway
function
lysosom
involv
degrad
endocyt
autophag
regul
exogen
endogen
cellular
materi
includ
recycl
process
extracellular
materi
endocytos
endosom
intracellular
cargo
intern
autophagosom
fuse
lysosom
degrad
produc
energi
atp
product
sourc
molecul
macromolecul
mechanist
target
rapamycin
complex
play
key
role
lysosom
nutrient
sens
signal
lysosometonucleu
axi
regul
energi
metabol
factor
energi
level
type
ph
ion
channel
regul
other
decid
fate
catabol
process
lysosom
exocytosi
lysosom
content
favour
plasma
membran
pm
repair
bone
resorpt
immun
respons
elimin
pathogen
store
b
lysosom
ultim
cell
compart
digest
unwant
protein
materi
gener
macroautophagi
microautophagi
pathway
cytoplasm
materi
trap
lysosom
process
membran
invagin
chaperonemedi
autophagi
cma
gener
lipid
droplet
ld
degrad
lipophagi
subtyp
macroautophagi
activ
cytosol
lipas
cma
also
demonstr
particip
degrad
ld
perilipin
protein
phosphoryl
p
ampactiv
protein
kinas
ampk
help
chaperon
mechanist
target
rapamycin
complex
akt
also
known
protein
kinas
b
neg
regul
cma
exert
effect
transloc
complex
cma
situat
starvat
neg
regul
control
pleckstrin
homolog
domain
leucinerich
repeat
protein
phosphatas
phlpp
lysosom
stabil
effect
transcript
factor
eb
tfeb
translat
nucleu
tfeb
bind
coordin
lysosom
express
regul
clear
motif
regul
transcript
gene
elong
factor
ly
lysosom
rasrel
botulinum
toxin
substrat
endocyt
process
certain
cell
call
phagocyt
exampl
macrophag
intern
larg
particl
bacteria
microorgan
foreign
particl
age
red
blood
cell
exampl
form
phagosom
vital
finelyregul
evolutionarilyconserv
intracellular
pathway
continu
degrad
recycl
clear
unnecessari
dysfunct
cellular
compon
autophagi
crucial
cell
adapt
environ
maintain
cell
homeostasi
especi
stress
condit
cytosol
apparatu
meant
regul
protein
modif
store
transport
form
lipid
cytosol
compart
via
transgolgi
network
outsid
cell
process
secretori
pathway
lysosom
fuse
plasma
membran
empti
content
outsid
cell
process
play
import
role
plasma
membran
repair
bone
resorpt
immun
respons
elimin
pathogen
store
mainli
lysosom
storag
disord
lsd
group
heterogen
disord
caus
defect
lysosom
enzym
lead
accumul
unmodifi
unprocess
compon
lysosom
ultim
influenc
vital
pathway
cell
lsd
implic
variou
vital
system
human
bodi
includ
skeleton
brain
skin
heart
central
nervou
system
connect
differ
metabol
pathway
sulfatas
other
synthes
endo
plasmic
reticulum
deliv
transport
vesicl
via
divers
system
tag
recogn
receptor
mpr
membran
glucocerebrosidas
gcase
transport
lysosom
lysosom
integr
membran
ubiquit
express
type
iii
transmembran
glycoprotein
mainli
locat
endosom
lysosom
matur
lysosom
acid
intern
ph
lysosom
hydrolas
activ
lin
ing
known
glycocalyx
protect
intern
lysosom
perimet
acid
environ
lumen
acid
environ
maintain
activ
vacuolar
type
proton
adeno
sine
triphosphatas
v
atpas
har
energi
hydrolys
atp
drive
transloc
proton
v
membran
domain
review
elsewher
key
lysosom
protein
includ
struc
tural
protein
lysosomeassoci
membran
protein
protein
involv
traffick
fusion
solubl
n
ethylmaleimidesensit
factor
attach
protein
receptor
snare
rab
gtpase
transport
key
role
chaperonemedi
autophagi
cma
ion
channel
chlorid
channel
cation
channel
mucolipin
member
transient
receptor
potenti
trp
famili
also
known
ref
protein
deliv
ere
clathrin
adaptor
protein
phosphatas
alp
pathway
protein
transloc
lysosom
associatedprotein
protein
preferenti
express
immun
cell
although
concept
still
remain
controversi
two
lysosom
speci
convent
secretoryar
often
distinguish
base
physic
bio
chemic
function
properti
catabol
main
function
convent
lysosom
sever
lysosom
relat
organel
lro
mel
anosom
late
endosom
major
histocompat
complex
class
ii
mhcii
compart
miic
lytic
granul
neutrophil
eosinophil
basophil
mast
cell
cell
platelet
complement
function
mani
lro
act
profession
secretori
organel
lro
share
lysosom
major
typic
characterist
acid
environ
lysosom
transmembran
protein
fusion
properti
phagosom
other
addit
particular
properti
result
specif
cargo
exampl
melanosom
contain
melanosom
specif
transmembran
glycoprotein
natur
killer
cell
cell
contain
perforin
granzym
detail
mechan
biogenesi
secret
lro
remain
unclear
although
known
genet
defect
lro
involv
rare
autosom
recess
disord
character
reduc
pigment
chediakhigashi
diseas
hermanskypudlak
syndrom
secretori
lysosom
contain
mani
protein
addit
contain
convent
lysosom
particip
multipl
cell
func
tion
plasma
membran
repair
tissu
bone
regener
apoptot
cell
death
cholesterol
homeostasi
pathogen
defenc
cell
signal
lysosom
biogenesi
function
regul
basic
helixloophelix
leucin
zipper
transcript
factor
eb
tfeb
coordin
lysosom
expr
sion
regul
clear
network
fig
exampl
autophagi
crucial
process
immun
autoimmun
transcript
regul
tfeb
interestingli
lysosom
exocytosi
import
mani
immun
function
also
depend
tfeb
activ
moreov
demonstr
tfeb
orchestr
lysosom
ca
signal
fact
multipl
lysosom
process
depend
tfeb
activ
strengthen
role
master
regul
lysosom
function
like
transcript
factor
tfeb
undergo
phosphoryl
dephosphori
lation
via
differ
cytosol
lysosom
pathway
fig
process
regul
mechanist
target
rapamycin
complex
master
control
cell
growth
lysosom
crossroad
variou
degrada
tive
pathway
includ
endocytosi
phagocytosi
autophagi
fig
three
main
form
autophagi
describ
macroautophagi
extens
character
form
microautophagi
cma
initi
macroautophagi
doubl
membran
sequest
compart
term
phagophor
contain
cytoplasm
materi
form
matur
vesicl
call
autophagosom
cargo
degrad
vacuol
issu
fusion
autophag
vesicl
lysosom
call
autolyso
some
result
short
product
releas
back
cytosol
reus
accord
time
contest
observ
possibl
dispatch
miic
ultim
process
mhcii
molecul
load
present
cell
contrast
macroautophagi
microautophagi
character
direct
lysosom
engulf
cytosol
materi
lysosom
via
format
characterist
invag
inat
lysosom
membran
third
major
form
autophagi
cma
involv
recog
nition
substrat
protein
contain
kferq
like
motif
complex
fig
cma
two
protein
key
role
ensur
select
protein
degrad
via
cma
pathway
transloc
tar
gete
cytosol
protein
across
lysosom
mem
brane
review
elsewher
termin
step
autophagi
call
autophag
lysosom
reform
tubular
proto
lysosom
extrud
autolysosom
contain
lysosom
membran
com
ponent
matur
function
lysosom
step
sole
lysosom
biogenesi
process
also
includ
seri
element
tightli
correl
regul
autophagi
combin
autophagi
lysosom
involv
innat
adapt
immun
func
tion
includ
foreign
materi
recognit
bacteri
parasit
viral
activ
pattern
recognit
receptor
toll
like
receptor
tlr
nucleo
tide
oligomer
domain
like
receptor
antigen
process
present
especi
context
multipl
sclerosi
ms
demyelin
diseas
myelin
sheath
wrap
around
nerv
fibr
central
nervou
system
progress
destroy
immun
cell
possibl
also
autoantibodi
parkinson
diseas
pd
neurodegen
disord
symptom
includ
slow
movement
loss
fine
motor
control
owe
degener
dopamineproduc
neuron
substantia
nigra
cma
select
autophagi
pathway
protein
contain
signal
kferqlik
sequenc
target
chaperon
transloc
lysosom
via
transcript
factor
eb
tfeb
protein
play
pivot
role
regul
basic
cellular
process
lysosom
biogenesi
autophagi
control
lysosom
function
via
coordin
lysosom
express
regul
clear
gene
network
includ
gene
code
hydrolas
lysosom
membran
protein
proton
pump
vatpas
complex
addit
lysosomerel
process
autophagi
endocytosi
exocytosi
finelyregul
process
cell
form
doublemembran
sequest
compart
name
phagophor
matur
autophagosom
doubl
membranebound
vesicl
enclos
cellular
constitu
fuse
lysosom
form
phagolysosom
engulf
materi
digest
degrad
either
releas
extracellularli
via
exocytosi
releas
intracellularli
undergo
process
mhcii
molecul
cell
homeostasi
antibodi
pro
duction
induct
variou
immun
signal
co
stimul
cytokin
secret
besid
degrad
organel
lysosom
recent
recogn
cellular
signal
platform
play
import
role
nutrient
sens
addit
protein
complex
call
lysosom
nutrient
sens
machineri
discoveri
stress
induc
lysosom
tonucleu
signal
mech
anism
tfeb
support
key
role
lysosom
cellular
signal
lysosom
occupi
central
posit
main
tenanc
cellular
homeostasi
involv
exclus
infecti
agent
penetr
host
ti
sue
concomitantli
promot
immun
regul
lysosom
must
therefor
abl
respond
quickli
increas
decreas
function
variou
metabol
condit
aim
protect
cell
death
damag
lysosom
divers
size
shape
reason
total
understood
po
sibli
accord
posit
cytosol
andor
composit
lysosom
singl
cell
prone
act
defend
cell
given
wide
rang
function
lysosom
metabol
compart
cell
dysregul
activ
could
lead
impair
variou
element
cellular
metabol
machineri
includ
transport
bio
genesi
sugar
glycolysi
lipid
protein
nucleic
acid
metabol
pathway
phagocytosi
endo
cytosi
autophagi
although
underli
mech
anism
far
fulli
deciph
seen
lysosom
dysfunct
defect
fusion
vesicl
contain
cargo
commonli
observ
abnorm
proteinopath
neurodegen
di
eas
dysfunct
lysosom
affect
proper
activ
organel
peroxisom
synthesi
rough
endoplasm
reticulum
rer
substrat
cargo
intend
degrad
endolysosom
pathway
transport
lysosom
via
transgolgi
network
tgn
among
key
enzymat
system
involv
lysosom
enzym
transport
cargo
golgi
lysosom
best
studi
receptor
mpr
system
bind
newli
synthes
lysosom
hydrolas
tgn
deliv
prelysosom
compart
compon
synthes
late
golgi
compart
deliv
directli
lysosom
via
phosphatas
alp
pathway
lysosom
compon
enzym
lytic
enzym
kinas
membranebound
proteinscomplex
mechanist
target
rapamycin
mtor
transport
ion
channel
vacuolartyp
proton
adenosin
triphosphatas
vatpas
osteopetrosi
associ
transmembran
protein
chaperonemedi
transport
bestknown
target
site
lysosom
dysfunct
depict
figur
mani
pharmacolog
antagonist
agonist
exert
activ
potenti
correct
lysosom
dysfunct
therefor
repres
potenti
effect
pharmacolog
tool
clear
coordin
lysosom
express
regul
cq
chloroquin
hcq
hydroxychloroquin
mtor
complex
ptdin
raptor
regulatoryassoci
protein
mtor
ser
smooth
endoplasm
reticulum
tfeb
transcript
factor
eb
wwwnaturecomnrd
mitochondria
lead
excess
product
reac
tive
oxygen
speci
patholog
featur
associ
age
cancer
chronic
inflamm
neurolog
diseas
male
infertil
infect
dysregul
thu
central
lsd
also
implic
wide
rang
disord
includ
ing
autoimmun
neurolog
disord
autophagylysosom
network
control
tfeb
attract
consider
attent
lsd
heterogen
group
inherit
metabol
disord
incid
live
birth
disord
treatment
review
extens
elsewher
cover
rel
briefli
mutat
respons
lsd
larg
elucid
tabl
mani
result
dysfunct
particular
lysosom
hydrolas
lead
accumu
lation
substrat
hydrolas
exampl
gaucher
diseas
sphingolipid
glucocerebrosid
accumul
cell
particularli
macrophag
organ
includ
liver
spleen
owe
defi
cienci
enzym
gcase
certain
lsd
result
patholog
explain
natur
molecul
accumul
tabl
thu
abun
danc
cerebrosid
gangliosid
deposit
central
nervou
system
cn
patient
sphingo
lipid
storag
disord
type
ii
acut
infantil
neuronopath
gaucher
diseas
underli
sever
neurolog
symptom
disord
patient
pomp
diseas
caus
glucosidas
defici
high
level
non
degrad
glycogen
accumul
muscl
could
explain
observ
myopathi
howev
undegrad
materi
accumul
caus
observ
cellular
organ
patholog
mani
lsd
remain
unclear
accumul
undigest
macromol
ecul
monom
lsd
instig
format
secondari
product
ultim
escap
endosomalautophagiclysosom
pathway
lead
multipl
consequ
affect
organ
includ
brain
liver
spleen
heart
eye
muscl
bone
tabl
organel
alter
lsd
includ
endosom
autophagosom
lysosom
function
lysosom
format
reform
fusion
endosom
autophago
some
lysosom
abnorm
alter
sever
autophagi
process
also
describ
lsd
thu
deregul
mitophagi
result
accu
mulat
damag
mitochondria
occur
lsd
lead
major
inflammatori
consequ
specif
tissu
perturb
mitochondri
dynam
frequent
observ
link
increas
product
reactiv
oxygen
speci
atp
product
ca
imbal
lsd
reduc
macro
autophagi
activ
decreas
autophag
flux
rather
hyperact
autophagi
process
seen
numer
autoimmun
diseas
seem
respons
accumul
non
degrad
cytoplasm
pro
tein
synuclein
huntingtin
htt
other
mucolipidosi
type
iv
tabl
diseas
character
sever
neurolog
ophthalmolog
abnorm
iti
caus
mutat
gene
inherit
autosom
recess
manner
gene
encod
non
select
cation
channel
mucolipin
recent
shown
requir
effi
cient
fusion
late
endosom
autophagosom
lysosom
impair
autophagosom
degrada
tion
result
accumul
autophagosom
lsd
microautophagi
process
involv
de
novo
synthesi
nascent
vacuol
also
appear
impair
lsd
notabl
reveal
primari
myoblast
patient
muscl
wast
con
dition
pomp
diseas
final
defect
cma
compo
nent
could
also
lead
lysosom
dysfunct
exampl
mutat
gene
claim
caus
danon
diseas
inherit
x
link
domin
pattern
investig
need
support
assert
lysosom
involv
pathway
central
immun
system
includ
degrad
intra
cellular
extracellular
materi
plasma
membran
repair
cell
death
signal
cell
homeostasi
death
although
direct
involv
lysosom
immun
far
fulli
understood
long
expect
lysosom
dysfunct
major
impact
immun
diseas
tabl
strikingli
howev
field
extens
explor
howev
elev
level
lysosom
enzym
activ
report
occur
sever
autoimmun
diseas
ra
system
lupu
erythematosu
sle
dermatomyos
psoriasi
discuss
autophagosom
form
autophagi
process
must
fuse
lysosom
gener
mitophagi
key
process
select
disrupt
damag
mitochondria
autolysosom
degrad
prevent
excess
reactiv
oxygen
speci
activ
cell
death
htt
discov
htt
protein
kda
wide
express
within
central
nervou
system
structur
elucid
recent
cryoelectron
microscopi
protein
essenti
embryon
develop
neurogenesi
involv
transcript
vesicl
transport
protein
traffick
endocytosi
autophagi
sle
chronic
relapsingremit
autoinflammatori
syndrom
multipl
heterogen
symptom
includ
arthralgia
swollen
joint
fever
fatigu
chest
pain
kidney
inflamm
cardiovascular
diseas
neuropsychiatr
complic
aetiolog
mostli
unknown
reduct
caus
reduc
lysosom
breakdown
mannosebas
oligosaccharid
mani
tissu
inherit
lsd
character
immun
defici
suscept
infect
includ
pulmonari
infect
facial
skelet
abnorm
hear
impair
intellectu
deficit
fabri
diseas
reduc
lysosom
metabol
lipid
globotriaosylceramid
caus
vascular
diseas
cardio
cerebro
renal
diseas
patient
gaucher
diseas
type
accumul
glucosylceramid
leukocyt
especi
macrophag
lead
abnorm
viscer
organ
type
neurolog
defect
children
adult
type
gangliosidosi
abnorm
lysosom
storag
oligosaccharid
caus
skelet
manifest
neurolog
impair
human
krabb
diseas
globoid
cell
leukodystrophi
defect
galactocerebrosidas
provok
accumul
galactosylceramid
galactosylsphingosin
psychosin
patient
brain
histolog
show
myelin
loss
neuroinflamm
axon
degener
arylsulfatas
saposinb
activ
protein
rare
case
defect
enzym
lead
accumul
sulfogalactosylceramid
major
organ
affect
differ
age
group
human
develop
sign
symptom
diseas
mucopolysaccharidos
enzym
involv
mucopolysaccharid
catabol
accumul
mucopolysaccharid
within
lysosom
lead
skelet
joint
abnorm
human
multipl
sulfatas
defici
formylglycinegener
enzym
need
activ
sulfatas
abnorm
accumul
multipl
includ
sulfat
glycosaminoglycan
caus
neurodegener
psychomotor
retard
human
pomp
diseas
accumul
undegrad
glycogen
muscl
peripher
nerv
observ
human
sandhoff
diseas
b
enzym
defect
caus
accumul
lysosom
induc
nervou
system
damag
human
mucolipidosi
type
ii
iii
nacetyl
glucosamin
phosphoryl
transferas
enzym
defici
result
accumul
unphosphoryl
glycoprotein
caus
motor
function
neurolog
disord
human
mucolipidosi
iv
mucolipini
defect
lysosom
membran
protein
ca
channel
caus
accumul
mucopolysaccharid
lipid
therebi
result
hepatosplenomegali
dysmorph
featur
neurolog
disord
human
cystinosi
cystinosin
cystein
transport
defect
lysosom
transport
cystinosin
caus
accumul
cystin
differ
organ
first
kidney
later
organ
human
danon
diseas
l
defect
l
especi
l
caus
accumul
glycogen
autophag
compon
cardiomyocyt
human
result
cardiac
diseas
l
highli
express
brain
cardiac
skelet
muscl
defect
autophagi
process
observ
sg
mrllpr
mice
crohn
diseas
abnorm
lysosom
ph
deregul
protonsens
g
proteincoupl
receptor
observ
mice
human
wwwnaturecomnrd
peptid
epitop
process
clear
possibl
deleteri
apoptot
debri
fuel
amino
acid
pool
produc
energi
fig
deviat
com
plex
process
affect
crucial
immun
cell
function
control
cytokin
releas
autoimmun
cell
anergi
program
cell
death
type
apop
tosi
type
ii
autophagi
secretori
lysosom
regul
releas
pro
inflammatori
anti
inflammatori
cytokin
process
depen
dent
type
stimul
addit
lysosom
degrad
glucocorticoid
receptor
essenti
bind
glucocorticoid
although
reason
known
complex
system
lysosom
execut
anti
inflammatori
action
via
phospholipas
pathway
also
induc
inflam
mation
pathway
condit
pro
inflammatori
anti
inflammatori
lysosom
act
indirect
precursor
autoimmun
howev
induct
suppress
inflammatori
signal
stimulu
depend
lysosom
cathepsin
central
role
degrad
biolog
macromolecul
lysosom
immun
respons
approxim
member
larg
proteas
famili
endo
peptidas
cleav
peptid
bond
protein
substrat
cathepsin
g
serin
proteas
cathepsin
e
aspart
proteas
cathep
sin
b
c
f
h
k
l
v
x
w
cystein
pro
teas
exampl
cathepsin
respons
degrad
antigen
autoantigen
antigen
present
cell
dendrit
cell
macrophag
b
cell
therefor
involv
upstream
level
present
mhcii
auto
antigen
peptid
complex
cell
cathepsin
l
preferenti
cleav
peptid
bond
aromat
residu
posit
hydrophob
residu
posit
central
antigen
process
bone
resorpt
tumour
invas
metastasi
turnov
intra
cellular
secret
protein
involv
growth
regu
lation
cathepsin
l
defici
mice
display
less
adipos
tissu
lower
serum
glucos
insulin
level
insulin
receptor
subunit
glucos
transport
type
fibronectin
wild
type
control
cathepsin
g
primarili
known
function
kill
digest
engulf
pathogen
also
involv
connect
tissu
remodel
site
inflamm
anti
neutrophil
cytoplasm
antibodi
react
cathepsin
g
identifi
patient
sle
abnorm
antigen
process
present
known
one
upstream
event
perturb
immun
respons
sle
process
mediat
lysosom
ration
specul
lyso
somal
function
could
alter
lupu
interestingli
hypothes
rais
lysosom
fragil
lupu
without
much
pursuit
composit
fluiditi
lysosom
mem
brane
effect
crucial
regul
lyso
somal
fusion
vesicular
organel
lysosom
uptak
macromolecul
integr
lysosom
membran
also
ensur
prevent
releas
lysosom
enzym
cytoplasm
lysosom
enzym
releas
fragil
lysosom
regard
potenti
harm
lupu
autoimmun
diseas
cont
lysosom
abnorm
splenic
b
cell
fa
defici
murphi
roth
larg
mrl
lpr
mice
mous
model
lupu
compar
b
cell
healthi
cbaj
mice
tfeb
express
increas
indic
enhanc
biogenesi
lysosom
lysosom
volum
rais
express
level
cathepsin
also
increas
result
reinforc
previou
data
show
expr
sion
activ
lysosom
enzym
cathepsin
l
b
play
import
role
antigen
process
alter
lupu
autoimmun
diseas
substanti
variat
acid
endo
lysosom
ph
also
occur
mrllpr
mice
rais
ph
unit
splenic
b
cell
ph
chang
could
dramat
ical
influenc
activ
solubl
lysosom
hydro
lase
cathepsin
well
lysosom
membran
protein
lamp
critic
lysosom
activ
ph
may
also
affect
elimin
immun
complex
accumul
lupu
result
deficit
complement
lower
express
scaveng
receptor
increas
express
receptor
rea
son
immun
complex
contain
non
select
igg
antibodi
autoantibodi
associ
autoantigen
includ
apoptot
debri
initi
inflamm
tissu
deposit
exampl
kidney
skin
gener
ca
cade
deleteri
effect
releas
harm
cytokin
chemokin
recent
studi
highlight
key
role
mam
malian
target
rapamycin
complex
disrupt
lysosom
acidif
occur
process
normal
condit
regul
lyso
somal
acidif
requir
cleavag
rab
small
gtpase
occur
surfac
phago
cytic
vesicl
local
activ
fine
regu
late
process
requir
associ
cofilin
actin
surround
vesicl
recruit
activ
ref
lupu
prone
macro
phage
chronic
activ
enhanc
cofilin
phosphoryl
therebi
hamper
associ
actin
affect
downstream
cascad
event
lead
appropri
acidif
lysosom
import
establish
earlier
lupu
cell
particular
context
activ
increas
wherea
activ
reduc
addit
lysosom
cathepsin
k
seen
contrib
ute
patholog
event
develop
fa
lpr
mice
anoth
model
lupu
diseas
part
activ
proteolyt
process
subsequ
effect
regulatori
cell
cathepsin
k
defici
fa
lpr
mice
reduc
kidney
patholog
manifesta
tion
glomerulu
tubulointerstiti
score
glo
merulu
complement
fraction
igg
deposit
chemokin
express
macrophag
infiltr
decreas
level
potenti
pathogen
serum
autoantibodi
line
intern
alter
lysosom
notabl
relat
cathepsin
function
deregu
lation
autophagi
report
contribut
lupu
patholog
autophagi
failur
describ
lymphocyt
mrllpr
mice
nzbxnzw
mice
two
spontan
murin
model
system
autoimmun
distinct
genet
ori
gin
display
differ
mhc
haplotyp
well
b
lymphocyt
patient
sle
murin
human
cell
peripher
blood
show
signific
accumul
autophag
vac
uol
compar
normal
underli
reason
dysfunct
autophagi
observ
lupu
clearli
understood
sever
indepen
dent
investig
identifi
risk
loci
span
autophagi
link
gene
patient
lupu
recent
studi
demonstr
increas
level
macroautophagi
salivari
gland
lymphocyt
tear
conjunctiv
epitheli
cell
patient
primari
syndrom
sj
alter
cma
activ
also
recent
found
occur
salivari
gland
mrllpr
mice
develop
second
ari
sj
like
diseas
lysosom
discuss
mechanist
involv
downstream
level
macroautophagi
cma
found
alter
salivari
gland
flow
cytometri
analys
reveal
mean
ph
acid
vesicl
mrl
lpr
salivari
gland
significantli
higher
compar
mous
control
gland
atp
con
tent
significantli
diminish
mrllpr
salivari
gland
cell
furthermor
amount
sever
leukocyt
glycosidas
proteas
reveal
increas
leukocyt
patient
sj
comparison
healthi
control
notabl
rais
level
lyso
somal
enzym
glucosidas
glucuronidas
dipeptidyl
peptidas
involv
tissu
injuri
sj
increas
express
lacrim
gland
cathepsin
also
report
may
applic
diag
nostic
tool
sj
two
member
ra
oncogen
famili
found
implic
regul
cathepsin
secret
level
sj
vitro
studi
lacrim
gland
acinar
cell
suggest
secret
acinar
cell
increas
cathepsin
express
stimul
mhcii
mediat
antigen
present
ocular
pathogenesi
sj
lysosom
cathepsin
import
role
induc
tion
diagnosi
ra
level
sever
cathepsin
b
g
k
l
present
serum
synovi
fluid
patient
propos
basi
ra
diagnosi
cathepsin
cathepsin
l
highli
express
synovi
macrophag
thymic
cortic
cell
exert
essenti
role
posi
tive
select
cell
antigen
present
respec
tive
particip
local
inflamm
matrix
degrad
occur
joint
cathepsin
b
involv
collagen
degrad
lead
joint
destruct
ra
express
cathepsin
g
particip
joint
inflamm
chemoattract
activ
shown
rais
synovi
fluid
patient
ra
compar
individu
osteoarthr
autoantibodi
wwwnaturecomnrd
react
cathepsin
g
also
identifi
patient
ra
compar
patient
osteoarthr
cathepsin
k
express
found
elev
ra
genet
delet
particular
cathepsin
shown
reduc
inflamm
bone
eros
ra
condit
via
tlr
mediat
neurolog
autoimmun
diseas
ms
myasthenia
gravi
syndrom
chronic
inflammatori
demyelin
polyneuropathi
cidp
neuromyel
optica
neuropsychiatr
lupu
neurolog
diseas
induc
abnorm
auto
immun
neurolog
autoimmun
variou
protein
myelin
ms
n
methyl
aspart
receptor
neuropsychiatr
lupu
affect
variou
structur
within
cn
peripher
nervou
system
divers
consequ
although
exact
caus
amyotroph
later
sclerosi
al
still
remain
unknown
studi
support
exist
auto
immun
mechan
al
therefor
also
includ
section
inde
autoantibodi
ganglio
side
sulfoglucuronylparaglobosid
neurofila
protein
voltag
gate
ca
channel
report
patient
al
review
elsewher
gener
origin
breakdown
immun
toler
occur
set
neurolog
diseas
known
recent
investig
discov
ere
autophagi
process
alter
diseas
ms
experiment
auto
immun
encephalomyel
experiment
model
ms
upregul
protein
kinas
mtor
describ
treatment
rapamycinsirolimu
immunosuppress
inhibit
mtor
cons
quentli
stimul
macroautophagi
amelior
clinic
histolog
sign
diseas
increas
level
macroautophagi
marker
measur
blood
brain
patient
ms
howev
impair
macroautophagi
found
spinal
cord
experiment
autoimmun
encephalomyel
mice
rat
model
mimick
human
cidp
macro
autophagi
cma
process
found
hyper
activ
lymphat
system
cell
non
neuron
cell
sciatic
nerv
peripher
nervou
system
cell
al
current
data
conflict
data
suggest
activ
macroautophagi
process
accumul
autophagosom
brain
tissu
patient
al
increas
autophag
vacuol
aggreg
ubiquitin
protein
associ
ii
motor
neuron
mice
develop
al
like
diseas
contrast
data
suggest
reduct
autophagi
activ
mutat
valosin
contain
protein
dynactin
pro
tein
complex
activ
dynein
motor
protein
enabl
intracellular
transport
member
small
gtpase
import
process
endosom
autophagosom
matur
also
describ
al
studi
requir
better
understand
type
extent
autophagi
dysfunct
famili
complex
diseas
publish
studi
lyso
somal
dy
function
neurolog
autoimmun
diseas
tabl
notabl
includ
lysosom
fragil
observ
patient
ms
white
matter
cerebr
tissu
area
cn
mainli
made
myelin
axon
lysosom
fragil
also
suspect
sle
see
rheumat
auto
immun
diseas
albeit
organ
note
signific
variat
lysosom
ph
measur
autoimmun
condit
lupu
sj
knowledg
studi
conduct
brain
element
peripher
nervou
system
patient
anim
model
neurolog
autoimmun
diseas
publish
cidp
shown
schwann
cell
dedif
ferenti
immatur
state
dediff
entiat
cell
activ
lysosom
proteasom
protein
degrad
system
base
observ
schwann
cell
claim
activ
particip
demyelin
process
via
dedifferenti
process
mechan
involv
remain
und
fine
rat
model
cidp
mention
shown
express
drastic
increas
sciatic
nerv
macrophag
reduc
macroautophagi
observ
schwann
cell
macrophag
ms
studi
conduct
white
matter
demon
strate
lysosom
involv
myelin
sheath
degener
well
fragment
protein
forma
tion
lysosom
swell
observ
near
degen
erat
materi
astrocyt
accumul
lipid
found
hypothes
lyso
somal
swellingpermeabil
might
caus
releas
hydrolas
cytosol
affect
nativ
protein
al
patient
also
show
dysfunct
endo
lysosom
pathway
affect
lower
upper
motor
neuron
tabl
cathepsin
b
particularli
found
involv
motor
neuron
degener
wherea
cathepsin
h
l
significantli
affect
cdna
microarray
analysi
post
mortem
spinal
cord
specimen
four
sporad
patient
al
reveal
major
chang
express
mrna
gene
includ
increas
express
cathepsin
b
sever
diseas
caus
mutat
gene
relat
autophagi
identifi
fu
optn
ref
none
code
lyso
somal
protein
crucial
remain
issu
clearli
determin
whether
lysosom
abnorm
observ
link
intrins
default
lysosom
result
upstream
dysregul
autophagosom
format
fusion
insuffici
clearanc
neurotox
protein
autophagylysosom
network
implic
numer
neurodegen
disord
disord
ad
huntington
diseas
hd
pd
modi
fie
misfold
protein
abnorm
accumul
specif
region
brain
accumul
aggreg
protein
also
seen
al
see
abnor
mal
protein
form
deposit
intracellular
inclus
extracellular
aggreg
characterist
caus
antibodi
target
muscl
acetylcholin
receptor
neuromuscular
junction
protein
musclespecif
kinas
antibodi
compromis
commun
nerv
muscl
lead
muscular
weak
fatigu
chronic
inflammatori
demyelin
polyneuropathi
cidp
progress
autoimmun
disord
peripher
nerv
root
trunk
brachial
plexus
damag
owe
demyelin
caus
muscl
weak
sensori
loss
reduc
reflex
also
known
devic
syndrom
diseas
character
inflamm
demyelin
optic
nerv
optic
neuriti
spinal
cord
myeliti
antibodi
react
water
channel
brain
patient
implic
neuromyel
optica
al
also
known
motor
neuron
diseas
diseas
gener
start
muscl
twitch
weak
limb
slur
speech
affect
control
muscl
need
move
speak
eat
breath
fatal
natur
review
drug
discoveri
diseas
although
substanti
research
field
still
unclear
sophisti
cate
qualiti
control
system
lysosomeautophagosom
system
particular
fail
certain
cir
cumstanc
protect
brain
protein
accumul
ad
one
common
neurodegen
disord
alter
endolysosom
path
way
describ
review
elsewher
amyloid
precursor
protein
app
cleav
secretas
amyloid
peptid
fragment
particularli
ref
fragment
found
amyloid
plaqu
one
hallmark
ad
neurofibrillari
tangl
contain
phosphoryl
tau
wide
consid
import
role
ad
pathogen
esi
cell
base
experi
demonstr
lysosom
cathepsin
role
gener
peptid
cathepsin
e
degrada
tion
peptid
cathepsin
b
lysosom
dy
function
observ
patient
ad
accumul
fragment
neuron
cell
shown
lead
lysosom
membran
alter
ation
caus
neuron
cell
death
context
noteworthi
inhibit
cathepsin
involv
lysosom
dysfunct
notabl
cleavag
tau
protein
tangl
like
fragment
diminish
hyperphosphoryl
brain
patient
ad
addit
patient
ad
inherit
form
diseas
may
carri
mutat
presenilin
protein
app
apolipoprotein
e
result
increas
product
longer
form
fragment
review
els
mutat
instanc
lead
direct
disrupt
lysosom
acidif
due
impair
deliveri
subunit
v
atpas
proton
pump
respons
control
intracellu
lar
extracellular
ph
cell
acidif
defi
cit
caus
excess
releas
lysosom
ca
channel
numer
deleteri
effect
find
strongli
support
hypothesi
dysfunct
endolysosom
pathway
pivot
ad
approxim
patient
pd
famili
histori
disord
although
underli
molec
ular
mechan
remain
unclear
context
lysosom
dysfunct
notabl
com
mon
known
pd
genet
mutat
encod
lysosom
gcase
gene
underli
gaucher
diseas
present
patient
pd
unit
state
mutat
also
associ
dementia
lewi
bodi
sever
gene
link
pd
directli
indirectli
relat
endolysosom
machineri
mutat
snca
code
synuclein
hallmark
pd
presenc
neuron
protein
inclus
call
lewi
bodi
mainli
com
pose
fibrillar
synuclein
synuclein
protein
normal
degrad
lysosom
cma
pathway
macro
aggreg
synuclein
mutant
display
longer
half
life
compar
non
aggreg
wild
type
protein
degrad
pathway
rather
would
degrad
via
macro
autophagi
pathway
shown
mutant
protein
bind
inhibit
transloc
substrat
therefor
final
degrad
biochem
analys
suggest
synuclein
mainli
degrad
lysosom
proteas
notabl
cathepsin
rather
non
lysosom
proteas
exampl
calpain
accumul
synuclein
observ
cathepsin
defici
mice
wherea
convers
accumul
synuclein
aggreg
reduc
transgen
mice
express
cathepsin
result
protect
dopaminerg
neuron
cell
damag
hd
rare
autosom
domin
neurodegen
ativ
diseas
caus
aberr
expans
cag
trinucleotid
repeat
within
exon
htt
gene
result
product
aggreg
prone
htt
mutant
mhtt
detriment
neu
ron
wherea
htt
protect
role
neuron
apoptosi
accumul
mhtt
howev
induc
pathophysiolog
consequ
includ
lysosom
autophagi
dysfunct
thu
mhtt
perturb
post
golgi
traffick
lysosom
compart
ment
deloc
complex
turn
affect
lysosom
function
excess
mhtt
induc
accumul
clathrin
adaptor
com
plex
golgi
increas
clathrin
coat
vesicl
vicin
golgi
cisterna
activ
sever
cathepsin
b
e
l
z
also
link
hd
cathepsin
respon
sibl
full
degrad
htt
less
effici
degrad
mhtt
process
cathepsin
l
cathepsin
z
also
cleav
htt
elong
poli
glutamin
tract
thu
lysosom
modul
act
cathepsin
activ
might
benefici
effect
treatment
hd
notabl
hyperexpress
cathepsin
cathepsin
b
shown
protect
primari
neuron
mhtt
toxic
alter
macro
autophagi
mitophagi
cma
also
implic
hd
cma
activ
increas
respons
macroautophagi
failur
earli
stage
hd
result
support
find
import
role
clearanc
htt
shrna
mediat
silenc
increas
aggreg
mhtt
studi
focus
htt
secretori
pathway
reveal
mhtt
secret
mediat
ca
depend
lyso
somal
exostosi
mechan
via
synaptotagmin
sensor
cell
extracellular
releas
mhtt
effici
inhibit
phosphoinositid
kinas
sphingomyelinas
inhibitor
hd
depend
perinuclear
local
lysosom
also
demonstr
increas
evid
thu
implic
lysosom
autophagi
dysfunct
pathogenesi
neuro
degen
disord
tfeb
receiv
particular
attent
regard
recent
data
suggest
tfeb
select
lost
patient
ad
well
al
increas
tfeb
activ
might
therefor
prevent
neuron
death
restor
neuro
nal
function
certain
neurodegen
diseas
includ
pd
major
microtubuleassoci
protein
matur
neuron
hyperphosphoryl
tau
accumul
ubiquitin
age
neuron
neurofibrillari
tangl
identifi
numer
neurodegen
diseas
call
tauopathi
includ
alzheim
diseas
lysosom
therapeut
target
given
evid
discuss
variou
lyso
somal
pathway
compon
could
repres
potenti
pharmacolog
target
wide
rang
diseas
consid
lysosom
target
import
note
need
specif
agent
target
lysosom
specif
tar
get
lysosomeslysosom
protein
defect
certain
organ
tissu
cell
addit
inhibitor
activ
lysosom
compon
may
requir
depend
diseas
context
consider
interest
therapeuti
calli
target
differ
autophagi
pathway
includ
lysosom
depend
pathway
progress
discoveri
develop
small
molecul
biolog
target
process
review
extens
howev
therapi
specif
target
lysosom
compon
far
gener
found
effect
clinic
trial
one
gener
except
develop
ert
small
molecul
drug
lsd
box
topic
recent
comprehens
review
discuss
depth
import
target
lysosom
whole
autophagi
process
sever
reason
first
regard
ing
safeti
integr
role
lysosom
sever
key
physio
logic
process
mean
therapeut
window
pharmacolog
intervent
unaccept
side
effect
may
limit
exampl
azithromycin
antibiot
anti
inflammatori
properti
use
treatment
patient
chronic
inflammatori
lung
diseas
cystic
fibrosi
found
block
autophagi
macrophag
inhibit
intracellular
kill
ing
mycobacteria
within
therebi
increas
risk
mycobacteri
infect
second
diseas
autophagi
may
enhanc
certain
tissu
organ
compromis
other
exampl
spleen
salivari
gland
mrllpr
mice
phe
nomenon
make
highli
challeng
identifi
singl
drug
abl
correct
failur
unless
cell
specif
target
ing
molecul
could
incorpor
autophagi
activatorinhibitor
enabl
tissu
specif
precis
target
lysosom
special
cell
may
circumv
complex
dysregul
mecha
nism
autophagi
process
pathophysiolog
set
indic
current
arsen
lysosom
specif
target
drug
small
fact
mani
drug
claim
target
lysosom
compon
also
found
capabl
interact
sever
non
lysosom
receptor
limit
efficaci
safeti
one
exam
ple
provid
chloroquin
cq
line
compound
deriv
hydroxychloroquin
hcq
wide
prescrib
patient
rheumat
diseas
histor
also
prophi
laxi
treatment
malaria
fig
cq
hcq
lysosomotrop
agent
rais
intralyso
somal
ph
therebi
affect
overal
lysosom
function
impair
autophag
protein
degrad
fig
although
mechan
action
agent
fulli
elucid
well
establish
cq
hcq
display
pleiotrop
activ
impor
tant
deleteri
properti
certain
set
claim
oper
interact
directli
tlr
ligand
effect
lysosom
ph
exampl
toxic
cqhcq
particular
eye
cornea
macula
occurr
cardio
myopathi
remain
major
limit
observ
ocular
toxic
relat
total
cumul
dose
rather
daili
dose
therefor
becom
seriou
potenti
problem
case
long
term
use
sever
hcq
analogu
mimic
design
aim
retain
therapeut
activ
without
secondari
effect
furthermor
small
molecul
far
identifi
investig
mod
ulat
autophagi
andor
lysosom
function
exhibit
complex
pleiotrop
properti
affect
overal
function
lysosom
also
differ
autophagi
pathway
exampl
mtor
depend
mtor
independ
pathway
well
qualiti
control
mechan
affect
cell
lifedeath
balanc
di
cuss
sever
wide
use
molecul
exert
dual
sometim
opposit
effect
upstream
stream
molecular
event
autophagylysosom
network
sever
robust
assay
character
autophagi
acti
vator
inhibitor
well
lysosom
effector
current
avail
valid
tabl
howev
assay
inher
bias
necessari
use
sever
independ
vitro
vivo
approach
ascertain
reactiv
specif
novel
molecul
abl
modul
pathway
box
regard
tremend
work
recent
year
establish
intern
guidelin
standard
research
autophagi
particular
propos
relev
methodolog
monitor
autophagi
accept
whole
commun
uniqu
better
definit
term
concept
also
box
enzym
replac
therapi
lysosom
storag
disord
enzym
replac
therapi
ert
lysosom
storag
disord
lsd
involv
administr
function
version
defect
enzym
particular
lsd
follow
administr
enzym
deliv
target
cell
typic
mediat
mannos
receptor
break
substrat
lysosom
therebi
amelior
lsd
approach
pioneer
use
glucocerebrosidas
gcase
purifi
placenta
treat
patient
gaucher
diseas
recombin
version
gcase
introduc
follow
success
approach
treat
gaucher
diseas
recombin
enzym
approv
lsd
includ
fabri
diseas
mucopolysaccharidosi
mp
mp
ii
mp
vi
pomp
diseas
tabl
mani
ert
lsd
clinic
trial
although
ert
provid
effect
treatment
patient
lsd
limit
recombin
enzym
administ
intraven
inject
abl
cross
bloodbrain
barrier
effect
central
nervou
system
manifest
lsd
low
express
receptor
mediat
deliveri
cell
surfac
target
cell
also
challeng
effect
ert
lsd
exampl
pomp
diseas
level
express
mannos
receptor
skelet
muscl
cell
low
necessit
high
dose
ert
achiev
therapeut
effect
numer
develop
studi
address
limit
focu
enzym
modif
enabl
better
access
enzym
receptor
nanomateri
enabl
safe
effici
deliveri
enzym
via
intracerebroventricularintrathec
administr
adopt
commun
lead
much
ea
ier
understand
research
worldwid
guidelin
definit
use
investig
evalu
new
molecul
design
select
target
key
step
autophagi
develop
new
high
throughput
screen
method
autophagi
modul
pharmacolog
molecul
howev
even
sophist
detail
assay
reca
pitul
full
complex
integr
live
system
establish
clinic
trial
pipelin
specif
agonist
antagonist
autophag
activ
current
small
particularli
cma
tabl
fig
howev
high
throughput
screen
programm
identifi
small
molecul
ongo
yield
addit
therapeut
target
use
tool
small
molecul
specif
target
lysosom
even
rarer
tabl
fig
small
molecul
drug
develop
specif
particular
lsd
includ
substrat
reduct
therapi
small
molecul
chaperon
reach
market
small
molecul
candid
common
diseas
earlier
stage
develop
molecul
specif
act
lysosom
discov
high
throughput
screen
mostli
target
variou
lysosom
enzym
cathepsin
acid
sphingomyelinas
galactosidas
acid
glucocerebrosidas
chaperon
nacetyl
hexosaminidas
although
sole
present
lysosom
v
atpas
proton
pump
respons
control
intracellular
extracel
lular
ph
cell
cation
channel
locat
within
endosom
lysosom
membran
also
pertin
target
tabl
summar
availabil
iti
pharmacolog
tool
compound
progress
drug
develop
applic
broad
target
class
addit
ert
lsd
box
drug
discoveri
programm
also
focus
alter
nativ
small
molecul
base
approach
may
particularli
relev
lsd
affect
cn
due
lack
bloodbrain
barrier
penetr
ert
small
molecul
use
substrat
reduct
thera
pie
prevent
accumul
substrat
defec
tive
enzym
lsd
inhibit
enzym
involv
substrat
product
miglustat
first
drug
approv
earli
us
food
drug
administr
european
medicin
agenc
gaucher
diseas
niemannpick
diseas
type
c
europ
iminosugar
inhibit
glucosylceramid
synthas
gc
catalys
initi
step
format
mani
glycosphingolipid
within
cell
glycosphingolipid
tend
local
outer
leaflet
plasma
membran
cycl
within
cell
endocyt
pathway
involv
lysosom
inhibit
gc
therefor
reduc
deleteri
accumul
glycosphingolipid
within
lysosom
potenti
therapeut
benefit
di
eas
like
lsd
miglustat
also
inhibit
disaccharidas
gastrointestin
tract
result
diarrhoea
side
effect
eliglustat
anoth
gc
inhibitor
penetr
cn
also
approv
gaucher
diseas
gc
inhibitor
clinic
devel
opment
includ
lucerastat
miglustat
analogu
improv
safeti
profil
current
phase
iii
trial
fabri
diseas
fd
ibiglustat
penetr
cn
latter
clinic
develop
fd
phase
ii
gaucher
diseas
type
phase
ii
patient
pd
carri
mutat
gba
phase
ii
recent
find
gener
small
number
patient
suggest
possibl
link
pd
fd
also
exist
patient
pd
gaucher
diseas
gba
mutat
see
final
genistein
pleotrop
natur
product
inhibit
kinas
involv
regul
proteo
glycan
biosynthesi
also
affect
tfeb
function
phase
iii
trial
sanfilippo
syndrom
substrat
mimet
inhibit
lysosom
enzym
also
found
stabil
mutat
enzym
lsd
therebi
lead
restor
enzym
activ
suitabl
subinhibitori
concentr
use
enzym
remain
stabl
function
dissoci
inhibitor
pioneer
exam
ple
approach
migalastat
describ
bind
activ
site
galactosidas
mutat
fd
stabil
mutant
enzym
exampl
strategi
includ
afegostat
gaucher
diseas
fail
phase
ii
clinic
trial
due
lack
efficaci
pyrimethamin
sandhoff
diseas
taysach
diseas
ambroxol
gaucher
diseas
neurolog
symptom
tabl
agent
earlier
development
stage
includ
n
valienamin
competit
inhibitor
gaucher
diseas
n
acetylcystein
pomp
diseas
lobelin
azasugar
krabb
diseas
n
valienamin
indic
gangliosidosi
chemic
structur
pharmacolog
chaperon
describ
recent
final
altern
strategi
stabiliz
ing
mutant
enzym
bind
away
activ
site
also
investig
promis
exampl
approach
non
inhibitori
small
molecul
chaperon
gcase
discov
screen
molecul
improv
activ
mutant
enzym
treatment
reduc
lyso
somal
substrat
storag
level
dopamin
ergic
neuron
deriv
induc
pluripot
stem
cell
patient
gaucher
diseas
parkinson
ism
test
patient
pd
gba
mutat
await
although
promi
ing
conflict
viewpoint
still
remain
strength
small
molecul
base
approach
primarili
compound
bind
catalyt
site
enzym
may
risk
high
concentr
inhibit
rather
increas
activ
clinic
trial
therefor
requir
order
analys
robust
approach
cathepsin
modul
robust
genet
pharma
colog
preclin
investig
consist
show
regul
cathepsin
activ
favour
abli
improv
patholog
featur
certain
auto
immun
inflammatori
diseas
inhibitor
sever
cathepsin
b
l
k
describ
activ
evalu
rheumat
auto
immun
diseas
sle
ra
sj
neuro
degen
disord
notabl
ad
tabl
select
inhibit
cathepsin
potent
activ
site
inhibitor
known
roch
mitig
diseas
mrllpr
lupu
prone
mice
reduc
prim
ing
b
cell
dendrit
cell
plasma
cell
gener
promis
data
also
gener
murin
model
context
diabet
nephrop
athi
cardiovascular
diseas
studi
base
cathepsin
inhibitor
evalu
clinic
safeti
util
treat
patient
affect
autoimmun
inflammatori
diseas
cathepsin
k
highli
express
osteoclast
effi
cientli
degrad
type
collagen
major
compon
organ
bone
matrix
also
potenti
target
modul
lysosom
dysfunct
di
order
discuss
sle
yet
investi
gation
select
cathepsin
k
inhibitor
requir
determin
whether
target
strategi
might
appli
sle
inflammatori
condit
articular
manifest
major
compon
ra
ankylos
spondyl
psoriat
arthriti
other
note
howev
variou
cathepsin
k
inhibitor
pursu
postmenopaus
osteo
porosi
includ
odanacatib
merck
reach
phase
iii
trial
although
odanacatib
effect
develop
discontinu
due
increas
risk
stroke
treat
patient
cathep
sin
inhibitor
context
clinic
evalu
list
tabl
despit
multipl
effort
develop
select
pharma
colog
cathepsin
modul
import
concern
still
fluoresc
measur
flow
cytometri
fluoresc
microscopi
cellular
stain
acidotrop
dye
lysotrack
dye
simpl
use
quantit
state
manufactur
adapt
clinic
trial
set
western
blot
fluoresc
imag
lysosom
marker
l
l
etc
simpl
provid
inform
subcel
popul
limit
usag
primari
cell
hard
transfect
bsa
bovin
serum
albumin
l
amp
lysosomeassoci
membran
protein
na
avail
qpcr
quantit
pcr
tfeb
transcript
factor
eb
wwwnaturecomnrd
remain
regard
target
effect
due
activ
cathepsin
toward
cathepsin
present
non
relev
unwant
site
nonetheless
lie
biolog
clinic
effect
certain
cathepsin
inhibitor
activ
remain
consider
interest
could
guid
futur
therapeut
approach
report
v
atpas
multisubunit
atp
driven
proton
pump
best
known
role
acidif
endosom
lysosom
regul
function
v
atpas
may
impact
lyso
somal
activ
henc
acidif
spe
cializ
cell
divers
signal
pathway
autophagi
v
atpas
inhibitor
like
bafilomycin
concanamycin
non
select
compound
tabl
fig
inhibit
mammalian
non
mammalian
v
atpas
control
lysosom
ph
acid
vesicl
via
manner
fulli
stood
fig
mechan
bafilomycin
inhibit
autophag
flux
prevent
acidifi
cation
endosom
lysosom
bafilomycin
cq
also
affect
mitochondri
function
discov
recent
use
intact
neuron
benzolactoneenamid
salicylihalamid
lobatamid
oximidin
bafilomycin
concanamycin
also
much
less
potent
investig
v
atpas
regul
signal
pathway
need
identifi
specif
safe
molecul
regul
vital
proton
pump
ion
channel
modul
discuss
lysosom
ion
channel
master
element
lysosom
activ
therebi
cell
homeostasi
famili
trp
channel
essenti
wide
express
late
endosom
lysosom
preferenti
associ
ate
lysosom
membran
genet
mutat
lead
inactiv
caus
rare
genet
disord
call
mucolipidosi
type
iv
mliv
pharmacolog
activ
amelior
lysosom
function
cla
sical
associ
mliv
npc
certain
lsd
tabl
fig
thu
small
molecul
fig
identifi
screen
acti
vator
defin
activ
ref
display
addit
effect
combin
endogen
activ
phospha
ptdin
analogu
chlorin
thiophen
replac
methyl
group
show
greater
efficaci
activ
anoth
molecul
call
ml
fig
act
mucolipin
synthet
agonist
also
show
addit
effect
endogen
ptdin
channel
import
note
neurolog
diseas
well
indic
lysosom
acidif
defec
tive
see
interf
may
contraind
central
modul
lysosom
lipid
kinas
fyve
finger
contain
phosphoinositid
kinas
pikfyv
convert
ptdin
latter
regul
ca
releas
lysosom
lumen
requir
acidif
v
atpas
inactiv
pikfyv
lead
mani
patho
physiolog
problem
includ
neurodegener
immun
dysfunct
mostli
relat
impair
autophag
flux
alter
lysosom
traffick
ca
transport
biogenesi
swell
small
molecul
apilimod
fig
tabl
origin
identi
fie
inhibitor
tlr
induc
later
found
highli
specif
inhibitor
pikfyv
apilimod
evalu
clinic
trial
involv
sev
eral
hundr
patient
helper
helper
cell
mediat
inflammatori
diseas
crohn
di
eas
ra
psoriasi
well
toler
human
subject
normal
healthi
volunt
patient
inflammatori
diseas
clinic
trial
meet
primari
endpoint
develop
abandon
apilimod
current
evalu
clinic
trial
aim
defin
maximum
toler
dose
patient
b
cell
non
hodgkin
lymphoma
monitor
safeti
pharmacokinet
pharmacodynam
prelimi
nari
efficaci
anoth
select
inhibi
tor
pikfyv
tabl
fig
inhibitor
contain
fyve
type
zinc
finger
domain
found
significantli
reduc
surviv
primari
mous
hippo
campal
neuron
cultur
revers
impair
endo
somal
traffick
cell
mimick
effect
produc
deplet
pikfyv
small
interf
rna
also
found
block
retrovir
exit
bud
sever
paramet
use
evalu
lysosom
function
tabl
alter
lysosom
volum
import
sign
lysosom
dysfunct
observ
variou
diseas
autoimmun
syndrom
cancer
lysosom
storag
diseas
measur
stain
cell
acidotrop
dye
lysotrack
dye
immunoblot
lysosom
membran
protein
lysosomeassoci
membran
protein
variat
lysosom
volum
often
relat
chang
lysosom
biogenesi
assess
express
level
cellular
locat
transcript
factor
eb
tfeb
howev
precis
determin
lysosom
function
reli
measur
lysosom
lumin
ph
degrad
activ
sever
fluoresc
probe
measur
lysosom
ph
tabl
commerci
avail
abnorm
lysosom
ph
affect
lysosom
degrad
activ
follow
exampl
detect
degrad
endocytos
fluoresc
dqbsa
complement
activ
specif
enzym
cathepsin
b
l
test
use
commerci
avail
kit
lysosom
paramet
evalu
deepen
examin
lysosom
statu
includ
lysosom
membran
stabil
integr
lysosom
ca
ion
signal
exampl
tabl
lysosom
function
essenti
link
autophagi
activ
autophagi
lysosomaldepend
degrad
pathway
thu
seri
method
routin
appli
assess
macroautophagi
mous
model
patient
autoimmun
diseas
summar
ascertain
extent
autophagi
defect
combin
techniqu
western
blot
flow
cytometri
measur
autophagi
maker
fluoresc
imag
electron
microscopi
presenc
absenc
lysosom
proteas
inhibitor
recommend
sever
review
articl
describ
reliabl
method
dedic
measur
chaperonemedi
autophagi
cma
activ
increas
express
level
two
key
player
cma
shown
occur
mous
model
lupu
howev
note
increas
express
level
start
total
lysat
indic
cma
upregul
test
suffici
allow
firm
conclus
necessari
examin
express
level
purifi
lysosom
lysosomeenrich
fraction
natur
review
drug
discoveri
chaperon
modul
molecul
target
chaperon
protein
involv
lysosom
function
also
design
potenti
therapeut
applic
one
molecul
small
molecul
inhib
itor
key
element
cma
bind
nucleotid
bind
domain
act
atp
competit
inhibitor
atpas
chaperon
activ
mous
model
ad
mice
intraperiton
treatment
reduc
two
main
patholog
fea
ture
ad
amyloid
plaqu
pair
helic
filament
tau
accumul
improv
object
recognit
locat
episod
like
memori
anoth
molecul
phosphopeptid
tabl
fig
also
shown
interact
fig
lodg
nucleotid
bind
domain
howev
mechan
action
effect
addit
phosphoryl
analogu
nomin
peptid
initi
spot
cellular
screen
assay
use
overlap
peptid
cover
whole
spliceosom
protein
cell
collect
lymph
node
lupu
prone
mrllpr
mice
peptid
enter
b
cell
via
clathrin
coat
depend
endocytosi
process
reach
earli
endosom
late
endosomeslysosom
affect
cma
hyperactiv
lupu
like
hamper
cma
mediat
chaperon
ref
peptid
reduc
excess
express
observ
lupu
mice
alter
auto
antigen
present
mhcii
molecul
miic
compart
consequ
attenu
activ
autoreact
cell
signific
diminut
mhc
molecul
express
surfac
antigen
present
cell
measur
mice
receiv
peptid
intraven
patient
peripher
cell
treat
ex
vivo
peptid
downstream
consequ
activ
auto
reactiv
b
cell
differenti
autoantibodi
secret
cell
repress
cell
patient
lupu
longer
respond
ex
vivo
peptid
encompass
cell
epitop
effect
cma
demonstr
vitro
use
fibroblast
cell
line
stabli
express
cma
report
select
target
cmalysosom
process
effect
mitophagi
evalu
murin
model
mimick
rheumat
diseas
promis
result
notabl
mice
develop
sj
featur
mice
neuropsychiatr
lupu
symp
tom
rat
develop
cidp
like
diseas
disturb
cma
macroautophagi
sciatic
nerv
clinic
trial
includ
patient
sle
formul
mannitol
found
safe
non
immunogen
sever
subcutan
admin
istrat
peptid
show
signific
efficaci
multicentr
doubl
blind
phase
ii
trial
peptid
current
evalu
phase
iii
trial
unit
state
europ
mauritiu
con
tinuat
open
label
trial
includ
sever
hundr
patient
lupu
worldwid
plan
anoth
peptid
discov
con
trast
activ
cma
peptid
call
humanin
origin
identifi
sur
vive
neuron
patient
ad
found
directli
enhanc
cma
activ
increas
substrat
bind
transloc
lysosom
humanin
interact
stabil
bind
chaperon
cma
cargo
bind
lyso
somal
membran
result
import
humanin
shown
possess
cardioprotect
neuro
protect
properti
diseas
ad
cardio
vascular
diseas
stroke
myocardi
infarct
diabet
cancer
addit
target
discuss
emerg
potenti
lysosom
therapeut
target
strong
biolog
valid
yet
small
molecul
develop
target
exampl
like
pharmacolog
tractabl
lysosom
k
channel
call
impor
tant
maintain
membran
potenti
ph
stabil
lysosom
defici
may
play
critic
role
pd
pathogen
importantli
structur
recent
refin
anoth
target
ligand
yet
valid
channel
also
name
channel
channel
shown
diseas
reduc
cholesterol
efflux
lyso
some
aberrantli
modifi
neuron
fire
pattern
disrupt
lysosom
cholesterol
efflux
decreas
ptdin
chan
nel
activ
may
lead
aberr
neuron
activ
cholesterol
transport
ptdin
floppas
respons
declin
ptdin
consequ
modifi
electr
properti
diseas
neuron
dysfunct
activ
alter
level
ptdin
due
notabl
genet
mutat
might
also
involv
neuropathi
exampl
form
epilepsi
hd
pd
ad
al
friedrich
ataxia
although
experi
need
valid
link
discov
hyperexcit
cell
death
diseas
neurodegen
diseas
small
molecul
retigabin
anti
convuls
drug
keep
channel
open
might
rep
resent
import
therapeut
tool
channel
open
ligand
includ
deriv
anoth
promis
therapeut
target
sphingo
myelin
phosphodiesteras
defect
gene
encod
caus
niemannpick
diseas
type
type
b
convert
sphingomyelin
ceramid
also
phospholipas
c
activ
reduc
activ
acid
sphingomyelinas
associ
mark
decreas
lysosom
stabil
describ
patient
niemannpick
diseas
phenotyp
correct
treat
cell
recombin
final
specif
lysosom
protein
display
decis
role
cma
shown
overexpress
certain
patholog
set
certain
cancer
inflammatori
diseas
autoimmun
non
autoimmun
downregul
express
wwwnaturecomnrd
might
therapeut
benefici
mention
howev
indic
defect
latter
due
reduc
stabil
iti
cma
receptor
decreas
de
novo
synthesi
exampl
age
result
aggreg
lysosom
membran
pathogen
protein
synuclein
ubiquitin
carboxi
termin
hydrolas
deubiquitin
enzym
mutant
tau
known
amass
neurodegen
disord
see
target
therefor
remain
challeng
although
sever
strategi
may
envisag
exampl
control
de
novo
synthesi
ham
pere
multimer
lysosom
possibl
via
andor
chaperon
regul
degrad
rate
monom
reus
lysosom
challeng
outlook
current
research
lysosom
function
dysfunc
tion
reveal
novel
role
lysosom
diseas
pathogenesi
highlight
new
opportun
treat
lysosom
autophagi
relat
diseas
case
autophagi
modul
lysosom
activ
inhibit
must
investig
cau
tion
lysosom
activ
abnorm
reduc
enhanc
organ
tissu
other
anoth
scale
lysosom
activ
alter
certain
lysosom
other
within
cell
biodistribut
studi
vivo
must
undertaken
avoid
accumul
pharmaceut
healthi
organ
tissu
obviou
requir
safeti
ensur
drug
use
lysosom
modu
lator
particular
type
lysosom
diseas
increas
vulner
anoth
diseas
still
much
learn
intim
work
lysosom
due
abund
constitut
element
compris
vesicl
ad
complex
result
plastic
ion
channel
transport
acidif
swell
ing
vast
amount
protein
peptid
transloc
lysosom
digest
lytic
enzym
sensit
analysi
method
allow
import
inform
gener
lyso
somal
membran
protein
larg
major
transport
howev
mani
question
remain
relat
express
regul
reg
ulat
transloc
chaperon
activ
exampl
certain
cell
contain
call
secretori
lysosom
cytotox
cell
wherea
cell
subset
contain
convent
secretori
lyso
some
platelet
consid
larg
famili
endo
lysosom
vesicl
whole
notion
secretori
convent
lysosom
remain
matter
debat
mani
instanc
lysosom
act
basal
cell
metab
olism
organel
wherea
case
assist
regul
homeostasi
unconvent
secretori
pathway
known
lysosom
exocytosi
differ
signal
mechan
although
sever
assay
use
measur
activ
iti
lysosom
valid
worldwid
box
tabl
limit
includ
issu
associ
reliabl
perform
sensit
notabl
vivo
anoth
level
complex
come
inher
organel
heterogen
issu
tremend
import
unfortun
tool
equip
hand
today
virtual
imposs
examin
happen
lysosom
individu
patient
introduct
micro
fluidic
singl
cell
analysi
technolog
enabl
cellular
popul
character
huge
advanc
perform
howev
level
precis
yet
achiev
level
lysosom
know
lysosom
heterogen
natur
composit
activ
even
normal
set
equal
compet
autophagi
type
activ
current
obvious
focu
intens
research
although
certain
number
preclin
studi
involv
lysosom
regul
conduct
year
small
number
lysosom
target
therapeut
far
move
clinic
develop
ment
one
biggest
advanc
develop
strategi
would
identif
genet
sig
natur
would
allow
patient
like
respond
specif
therapi
select
howev
stage
knowledg
specif
lysosom
direct
drug
intrins
lysosom
failur
genet
featur
might
predict
potenti
respond
still
lack
except
lsd
investi
gation
requir
achiev
level
knowledg
obvious
also
depend
type
diseas
heterogen
frequenc
anoth
issu
associ
develop
lysosometarget
therapeut
relat
deliveri
use
nanovector
repres
attract
deliveri
method
owe
particular
uniqu
abil
penetr
across
cell
barrier
via
endo
lysosom
pathway
preferenti
home
orga
nell
lysosom
sever
nanoscal
galen
form
develop
serv
vector
car
rier
protein
peptid
nucleic
acid
vast
literatur
describ
mani
advantag
use
nano
structur
nanomedicin
howev
safeti
concern
carbon
nanostructur
claim
induc
nanotox
accompani
induct
autophagi
lysosom
dysfunct
review
elsewher
purpos
review
gain
awar
import
lysosom
diseas
encour
age
develop
novel
lysosom
target
drug
howev
research
need
character
com
ponent
specif
link
lysosom
clearli
defin
specif
involv
lysosom
biogenesi
metabol
special
attent
given
mode
administr
lysosom
target
medica
tion
order
minim
toxic
promot
specif
target
hope
larg
field
therapeut
applic
could
emerg
investig
encompass
rare
common
autoimmun
neuro
degen
metabol
diseas
well
cancer
senesc
age
natur
review
drug
discoveri
